Levosimendan Eql Pharma

Levosimendan, the active ingredient in Levosimendan Eql Pharma, is a calcium sensitizer / inodilator presented as a solution for infusion for intravenous use. It is indicated for the treatment of acute decompensated heart failure in adult patients and can improve hemodynamic status.

GNH USA supplies Levosimendan Eql Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, ensuring quality and regulatory compliance across global markets.

Levosimendan is employed in the management of acute decompensated heart failure, a condition marked by sudden worsening of cardiac function.

Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion.

Levosimendan may cause several adverse reactions during therapy.

Common Side Effects: - Hypotension: drop in blood pressure, especially during initial infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate. - Flushing: warm sensation and reddening of skin. - Vomiting: occasional emesis.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: marked blood pressure fall requiring intervention. - Myocardial ischemia: reduced blood flow to heart muscle. - Allergic reactions: rash, pruritus, or anaphylaxis. - Liver enzyme elevation: abnormal hepatic function tests. - Renal dysfunction: impaired kidney function.

Levosimendan requires careful monitoring and specific precautions before and during administration.

Monitor blood pressure: watch for hypotension, especially during loading dose. Monitor cardiac rhythm: observe for arrhythmias throughout infusion. Use with caution in renal impairment: adjust therapy based on renal function. Use with caution in hepatic impairment: consider reduced clearance. Contraindicated in severe hypotension: avoid use when systolic pressure is markedly low. Store at ambient temperature: keep in original packaging, protect from light and moisture.

Levosimendan can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Concurrent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may augment hypotensive effect. - ACE inhibitors: can enhance blood pressure reduction. - Digoxin: may increase risk of arrhythmias.